Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | F11 | P03951 | 2/20 | 0.51 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | HMGCR | P04035 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10260289 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL307746 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL3312921 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL309486 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL13021359 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL10338159 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL22983975 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL10056632 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL15833293 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA | |
| SCHEMBL22796983 | 1.00 | PTPN1 (0.59) | PTPN1TSHRPTPN2PTPN11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951098-B2 | Synthesis of 5-azacytidine | PHARMION LLC (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3134537-B1 | METHOD FOR THE SYNTHESIS OF CLOFARABINE | SYNBIAS PHARMA AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| EP-2691408-B1 | SYNTHESIS OF 5-AZACYTIDINE | CELGENE INT SÁRL (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170146517-A1 | COMPOUNDS AND METHODS USED IN ASSESSING MONO-PARP ACTIVITY | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| EP-2918275-A1 | Alternative nucleic acid molecules and uses thereof | Roy, Atanu (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140128593-A1 | SYNTHESIS OF 5-AZACYTIDINE | CELGENE INTERNATIONAL SARL (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128593-A1 | SYNTHESIS OF 5-AZACYTIDINE | CELGENE INTERNATIONAL SARL (US) | 2014-05-08 | — | — | US | disclosed |
| US-8648188-B2 | Preparation of 2-chloro-9-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-adenine | SCINOPHARM TAIWAN, LTD. (TW) | 2014-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PTPN1 3226/4885TSHR 2428/4885PTPN2 2802/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PTPN1 2834/4885TSHR 3169/4885PTPN2 2280/4885 |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PTPN1 3226/4885TSHR 2428/4885PTPN2 2802/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PTPN1 3226/4885TSHR 2428/4885PTPN2 2802/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PTPN1 2834/4885TSHR 3169/4885PTPN2 2280/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PTPN1 2834/4885TSHR 3169/4885PTPN2 2280/4885 |
| US-20170146517-A1 | COMPOUNDS AND METHODS USED IN ASSESSING MONO-PARP ACTIVITY | PARP3, PARP11, PARP1 | PTPN1 4597/4885TSHR 4817/4885PTPN2 4576/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PTPN1 3226/4885TSHR 2428/4885PTPN2 2802/4885 |
| US-20140128593-A1 | SYNTHESIS OF 5-AZACYTIDINE | AZI2, TET2, DNMT1 | PTPN1 2265/4885TSHR 2965/4885PTPN2 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.